An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults

Trial Profile

An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs RXI 109 (Primary)
  • Indications Hypertrophic scars
  • Focus Therapeutic Use
  • Sponsors RXi Pharmaceuticals
  • Most Recent Events

    • 18 Dec 2017 Results presented in an RXi Pharmaceuticals media release.
    • 18 Dec 2017 According to an RXi Pharmaceuticals media release, Joseph P. Hunstad is the principal investigator for the Company's Dermatology Clinical Program with RXI-109.
    • 18 Dec 2017 Primary endpoint (Reducing the recurrence of hypertrophic scar after scar revision surgery) has been met, according to an RXi Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top